JP2025509404A5 - - Google Patents
Info
- Publication number
- JP2025509404A5 JP2025509404A5 JP2024553774A JP2024553774A JP2025509404A5 JP 2025509404 A5 JP2025509404 A5 JP 2025509404A5 JP 2024553774 A JP2024553774 A JP 2024553774A JP 2024553774 A JP2024553774 A JP 2024553774A JP 2025509404 A5 JP2025509404 A5 JP 2025509404A5
- Authority
- JP
- Japan
- Prior art keywords
- pentyl
- heptyl
- octyl
- hexyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022080837 | 2022-03-15 | ||
| CNPCT/CN2022/080837 | 2022-03-15 | ||
| PCT/CN2023/081281 WO2023174250A1 (en) | 2022-03-15 | 2023-03-14 | 4- (aminomethyl) -6- (1-methyl-1h-pyrazol-4-yl) isoquinolin-1 (2h) -one derivatives as mta-cooperative inhibitors of prmt5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509404A JP2025509404A (ja) | 2025-04-11 |
| JP2025509404A5 true JP2025509404A5 (cg-RX-API-DMAC10.html) | 2026-03-18 |
Family
ID=88022264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553774A Pending JP2025509404A (ja) | 2022-03-15 | 2023-03-14 | Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250000854A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4493555A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025509404A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118871432A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023174250A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4574816A4 (en) * | 2022-07-07 | 2026-01-14 | Xizang Haisco Pharmaceutical Co Ltd | HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND ITS USE |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2025031468A1 (zh) | 2023-08-09 | 2025-02-13 | 江苏恒瑞医药股份有限公司 | 杂芳基化合物、其制备方法及其在医药上的应用 |
| CN121159457B (zh) * | 2025-11-20 | 2026-03-17 | 英矽智能科技(上海)有限公司 | Prmt5抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007075783A2 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
| MX2015006780A (es) * | 2012-12-31 | 2015-08-06 | Cadila Healthcare Ltd | Derivados de ftalazin-1-(2h)-ona sustituida. |
| GB201604027D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| CN120208880A (zh) * | 2019-09-12 | 2025-06-27 | 米拉蒂医疗股份有限公司 | Mta-协同prmt5抑制剂 |
| EP4304720A1 (en) * | 2021-03-11 | 2024-01-17 | Mirati Therapeutics, Inc. | Mta-cooperative prmt5 inhibitors |
-
2023
- 2023-03-14 EP EP23769752.9A patent/EP4493555A4/en active Pending
- 2023-03-14 WO PCT/CN2023/081281 patent/WO2023174250A1/en not_active Ceased
- 2023-03-14 JP JP2024553774A patent/JP2025509404A/ja active Pending
- 2023-03-14 CN CN202380026714.7A patent/CN118871432A/zh active Pending
-
2024
- 2024-09-05 US US18/825,776 patent/US20250000854A1/en active Pending